

Management of patients with heart failure with preserved ejection fraction: what do patients and providers need and want?

Submission date 08/06/2020	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 17/06/2020	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 05/10/2022	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of all cases of heart failure. In the UK 920,000 people are thought to be affected by heart failure and the number of people with HFpEF is thought to be growing due to the increasing prevalence of lifestyle diseases. Researchers previously conducted an interview study with patients and healthcare providers living with or managing HFpEF to try to work out what care patients received with the view to driving improvement. This was especially important as there is low awareness of this type of heart failure and inequality in service provision (e.g. some areas don't take on referrals for HFpEF as they are not funded to do so). This study has now concluded, however, all participants provided consent to be contacted about future linked research. The researchers now plan to undertake a COVID-19-related sub-study with this panel of participants to explore the experiences of this group in these unprecedented times. Due to COVID-19, many patients and providers have experienced changes in the care they receive/provide. The researchers would like to explore the impact of these changes in order to inform an ongoing programme of research (OPTIMISE HFpEF) which aims to design an optimised management pathway for people with HFpEF.

Who can participate?

Patients, carers and healthcare professionals who participated in OPTIMISE HFpEF (<https://clinicaltrials.gov/ct2/show/NCT03617848>) and who provided consent to be contacted about future research

What does the study involve?

This study involves either participating in an interview with a researcher that will be digitally recorded, or completing and returning a paper-based survey. Both the interview and the survey will ask participants about their experiences of receiving/providing healthcare in the run-up to, during and after the main wave of the COVID-19 pandemic.

What are the possible benefits and risks of participating?

The researchers do not perceive any risks to participating, surveys and interviews will be fully anonymised.

Where is the study run from?

1. University of Cambridge (UK)
2. Keele University (UK)
3. University of Manchester (UK)

When is the study starting and how long is it expected to run for?

June 2020 to November 2020

Who is funding the study?

The Healthcare Improvement Studies Institute (UK)

Who is the main contact?

Prof. Christi Deaton

cd531@medschl.cam.ac.uk

Study website

<https://www.optimisehfpef.phpc.cam.ac.uk/>

Contact information

Type(s)

Public

Contact name

Mrs Faye Forsyth

ORCID ID

<http://orcid.org/0000-0003-2107-3690>

Contact details

Primary Care Unit

Department of Public Health & Primary Care

Forvie Site

United Kingdom

CB2 0QQ

+44 (0)7921072847

fc349@cam.ac.uk

Type(s)

Scientific

Contact name

Prof Christi Deaton

ORCID ID

<http://orcid.org/0000-0003-3209-0752>

Contact details

Primary Care Unit
Department of Public Health & Primary Care
Forvie Site
United Kingdom
CB2 0QQ
+44 (0)1223 (3)30335
cd531@medschl.cam.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Version 4.0, dated 21/04/2020

Study information

Scientific Title

Management of patients with heart failure with preserved ejection fraction: what do patients and providers need and want? A qualitative and survey-based study

Study objectives

This study aims to understand what patients and providers would like/envision as optimal management of heart failure with preserved ejection fraction (HFpEF). This study is part of a larger programme of research. In April 2020 this study was amended so that the researchers could recall previous participants who provided 'consent to be contacted about future research' in order to understand perspectives since the onset of the COVID-19 pandemic.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 01/05/2020, North East - York Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)207 104 8091, +44 (0) 207 104 8079; york.rec@hra.nhs.uk), REC ref: 17/NE/0199

Study design

Observational cross-sectional qualitative and survey study

Primary study design

Observational

Secondary study design

Cross sectional study

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

<https://www.optimisehfpef.phpc.cam.ac.uk/>

Health condition(s) or problem(s) studied

Heart failure with preserved ejection fraction, impact of COVID-19 (SARS-CoV-2 infection) pandemic on healthcare received and provided

Interventions

Interviews will be performed via telephone or in person, digitally recorded and transcribed verbatim. Semi-structured interview schedules will guide questions. A survey exploring similar fields will be distributed to those who cannot commit to an interview, the survey employs Likert type scales and free text boxes to capture views, Likert responses will be quantified and free-text answers interrogated thematically. Participation is once only, there will be no follow-up.

Intervention Type

Other

Primary outcome measure

Perspectives on care provided and received since COVID-19, assessed using interview and survey at a single timepoint (baseline)

Secondary outcome measures

There are no secondary outcome measures

Overall study start date

01/06/2020

Completion date

01/11/2020

Eligibility

Key inclusion criteria

This is a recall study: patients, carers and healthcare professionals who participated in OPTIMISE HFpEF (<https://clinicaltrials.gov/ct2/show/NCT03617848>) and provided 'consent to be contacted' will be invited to participate

Participant type(s)

Mixed

Age group

Adult

Sex

Both

Target number of participants

50

Total final enrolment

50

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

08/06/2020

Date of final enrolment

01/11/2020

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre**University of Cambridge**

Institute of Public Health

Cambridge Biomedical Campus

Forvie Site

Cambridge

United Kingdom

CB2 0SR

Study participating centre**Keele University**

School of Primary, Community and Social Care, Faculty of Medicine and Health Sciences

David Weatherall Building, Room 1.109

Keele

United Kingdom

ST5 5BG

Study participating centre

University of Manchester

Division of Population Health, Health Services Research & Primary Care
Oxford Road
Manchester
United Kingdom
M13 9PL

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust

Sponsor details

S Block
Level 4
Addenbrooke's Hospital
Cambridge
England
United Kingdom
CB2 0QQ
+44 (0)1223 596472
rachel.kyd@addenbrookes.nhs.uk

Sponsor type

Hospital/treatment centre

Website

<https://www.cuh.nhs.uk/for-researchers>

ROR

<https://ror.org/04v54gj93>

Funder(s)

Funder type

Research organisation

Funder Name

The Healthcare Improvement Studies Institute

Results and Publications

Publication and dissemination plan

The protocol is available on the programme website: <https://www.optimisehfpef.phpc.cam.ac.uk/>. The researchers plan to submit a publication to a peer-reviewed journal and they will work with their respective communications teams to produce shorter summaries for participants.

Intention to publish date

30/11/2020

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available as the researchers do not have explicit consent to share the data, even in anonymised format, outwith the research team.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		26/11/2020	18/05/2021	Yes	No
Results article		05/01/2021	18/05/2021	Yes	No
Protocol article		26/11/2019	05/10/2022	Yes	No
Protocol file	version 2	26/07/2018	05/10/2022	No	No
HRA research summary			26/07/2023	No	No